Spero Therapeutics (SPRO) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic vision and portfolio focus

• Aims to lead in rare and infectious diseases, prioritizing high unmet need and strong economics.

• Portfolio includes SPR720 (oral NTM therapy), tebipenem (oral cUTI therapy), and SPR206 (next-gen polymyxin).

• Avoids markets crowded with generics or follow-ons.

• Active in business development, seeking assets aligned with core mandate.

• Plans to grow pipeline if new opportunities meet criteria of need and economics.

Key upcoming catalysts and timelines

• SPR720 phase IIa data expected in Q4 this year; resistance data to be presented at IDWeek.

• Tebipenem phase III enrollment to complete in H2 next year; NDA filing targeted for next year.

• SPR206 phase II progression contingent on non-dilutive funding.

SPR720: NTM therapy opportunity

• NTM is a debilitating lung disease with no approved first-line therapies; current care uses off-label TB drugs with poor tolerability.

• SPR720 could be the first oral therapy for first-line NTM patients.

• Preclinical and early clinical data show strong efficacy and safety.

• Market opportunity is significant, with first-line space much larger than current refractory market.